ELI LILLY & Co
Company Stats
- Market Cap
- $1.1T
- as of Sep 30, 2026
- Enterprise Value
- $1.1T
- Shares Outstanding
- 940.7M
- Free Float
- 90.1%
Income Statement
- Revenue
- $65.2B
- Net Income
- $20.6B
- Revenue Growth, 3Y
- 31.7%
- FCF Margin, 3Y Avg
- 8.1%
- FCF Margin, Worst Year
- 2.3%
Cash Flow
- Free Cash Flow
- $9.0B
- FCF Yield
- 0.8%
- Owner FCF Yield
- 0.8%
Balance Sheet
- Cash & Equivalents
- $7.3B
- Total Debt
- $42.5B
- Net Debt
- $35.2B
Returns & Capital
- Dividends Paid
- $5.4B
- Dividend Yield
- 0.5%
- Dividend Payout, 3Y Avg
- 49.3%
- Share Repurchases
- $4.1B
- Buyback Yield, 3Y Avg
- 0.2%
- SBC, 3Y Avg
- $633.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $65.2B | $9.0B | 13.8% |
| FY2024 | $45.0B | $3.8B | 8.3% |
| FY2023 | $34.1B | $792.0M | 2.3% |
| FY2022 | $28.5B | $5.7B | 20.1% |
| FY2021 | $28.3B | $6.1B | 21.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 6, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 31, 2026
Weekly Earnings
Earnings Roundup for Week of Oct. 26, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
Lilly’s Zepbound sets an approved benchmark for dual-agonist obesity drugs
September 23, 2026
Drug Pipeline
Lilly’s triple agonist retatrutide heads toward a planned US filing
September 23, 2026
Drug Pipeline
Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
September 23, 2026
Drug Pipeline
Lilly’s Omvoh follows induction with maintenance in ulcerative colitis
Earnings Roundup for Week of Oct. 26, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
Lilly’s Zepbound sets an approved benchmark for dual-agonist obesity drugs
September 23, 2026
Drug Pipeline
Lilly’s triple agonist retatrutide heads toward a planned US filing
September 23, 2026
Drug Pipeline
Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
September 23, 2026
Drug Pipeline
Lilly’s Omvoh follows induction with maintenance in ulcerative colitis